EPISODE · Apr 28, 2026
POOLBEG PHARMA PLC - FY25 Results
from Investor Meet Company - Audio Archive · host Investor Meet Company
Poolbeg Pharma PLC (POLB:AIM) delivered a focused full-year results investor update, highlighting strong company performance, a £7.7 million cash position and financial runway into 2027. The clinical-stage biopharma is advancing POLB 001, an oral p38 MAPK inhibitor targeting prevention of cytokine release syndrome in cancer immunotherapies, with MHRA approval secured, six UK cancer centres lined up and interim CRS trial data expected in summer 2026. Backed by Johnson & Johnson’s supply of teclistamab, growing IP protection, FDA orphan drug designation and positive human challenge data, Poolbeg sees a potential $10 billion market opportunity across multiple myeloma and lymphoma. Management also reported accelerating partnering discussions with large and mid-sized pharma companies, supported by a populated data room and strong payer feedback. Alongside POLB 001, the company is progressing an oral GLP-1 obesity programme, with a clinical trial expected in H2 2026, reinforcing its growth strategy, revenue potential and value inflection points.
NOW PLAYING
POOLBEG PHARMA PLC - FY25 Results
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Feb 8, 2026 ·4m
Feb 4, 2026 ·18m
Jan 30, 2026 ·6m
Jan 2, 2026 ·47m